Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705053 · ClinicalTrials.gov registry record · Phase 3
At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation
A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by Sansum Diabetes Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT02705053 is a Phase 3 study of Type 1 Diabetes Mellitus that has completed, run by Sansum Diabetes Research Institute. The registered enrollment target is 32 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02705053, a Phase 3 study of Type 1 Diabetes Mellitus, has completed, sponsored by Sansum Diabetes Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial is a study to assess the performance of an automated glucose control system (Artificial Pancreas, AP) device in home settings for subjects with type 1 diabetes. Specifically, the investigators will test zone model predictive control AP that will be enhanced by run-to-run optimizations of basal rates (BR) and insulin to carbohydrate ratios (CR).
Conditions Studied
Interventions
- DEVICE CGM and Insulin Pump
- DEVICE Closed-Loop Control System
Study Locations (3)
California
- William Sansum Diabetes Center - Santa Barbara
Minnesota
- Mayo Clinic - Rochester
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02705053
The ClinicalTrials.gov registry entry for NCT02705053 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (77% lower). The listed sponsor is Sansum Diabetes Research Institute, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which CGM and Insulin Pump is the first listed.
NCT02705053 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Minnesota, Virginia.
Frequently Asked Questions
What is clinical trial NCT02705053 about?
NCT02705053 is a clinical study titled "At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation". This clinical trial is a study to assess the performance of an automated glucose control system (Artificial Pancreas, AP) device in home settings for subjects with type 1 diabetes. Specifically, the investigators will test zone model predictive control AP that will be enhanced by run-to-run optimiza...
What is the current status of trial NCT02705053?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2016-02. Estimated completion is 2016-08.
What conditions does trial NCT02705053 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT02705053?
The interventions under investigation include: CGM and Insulin Pump (DEVICE), Closed-Loop Control System (DEVICE).
Who is sponsoring clinical trial NCT02705053?
This trial is sponsored by Sansum Diabetes Research Institute, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02705053 being conducted?
This trial has 3 study locations across California, Minnesota, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
RECRUITING · Phase 3
-
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Pediatric Diabetics Type 1 Using InsuPatch
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.